Back to search results

Understanding Mycosis Fungoides and Sezary Syndrome Prognosis

This observational study aims to better understand Mycosis Fungoides (MF) and Sezary Syndrome (SS), which are types of non-Hodgkin's lymphoma affecting the skin. Researchers are collecting health information from 2000 patients to identify factors that predict how the disease might progress. The goal is to create a tool that helps doctors identify patients at higher or lower risk for survival, ultimately improving care. This study is looking at overall survival (how long patients live after diagnosis) for up to two years. You may be able to join if you have advanced MF or SS (Stages IIB-IVB) and were diagnosed within the last six months. The study is currently unclear on its recruitment status.

Study design
This is an observational study planning to include 2000 participants. It is not testing a specific treatment but rather collecting information to understand the disease better.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Overall survival will be measured from the date of diagnosis up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02848274

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Recruiting
Not specifiedAll AgesObservational
Stanford University
~2,000 participants
Updated 2025-10-22 on ClinicalTrials.gov

At a glance

Recruiting sites
13 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall survival (OS)
Measured over date of diagnosis to death from any cause, up to two years

Conditions

Mycosis Fungoides
Non-Hodgkin's Lymphoma

Explore related trials

Mycosis FungoidesNon-Hodgkin LymphomaSezary Syndrome

Where it's being run

13 sites across 12 states
California2
Iowa1
New Jersey1
Pennsylvania1
Texas1
Utah1
Argentina1
Australia1

Study leadership

  • Youn H Kim, MD · PRINCIPAL_INVESTIGATOR · Stanford University

Who to contact

Tatiana Neal
[email protected]
650-709-7838
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center
Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available

Exclusion

Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage
Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center
Exclude one-time consultation type of new patients.

What this trial measures

  • Overall survival (OS)date of diagnosis to death from any cause, up to two years